Uniqure (NASDAQ:QURE) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Wednesday, January 10th.
According to Zacks, “UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company’s product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands. “
A number of other research analysts have also recently issued reports on the company. HC Wainwright set a $28.00 price objective on Uniqure and gave the company a “buy” rating in a research note on Thursday, December 7th. Leerink Swann lifted their price objective on Uniqure from $19.00 to $26.00 in a research note on Tuesday, November 7th. Oppenheimer reiterated a “hold” rating on shares of Uniqure in a research note on Friday, November 24th. ValuEngine upgraded Uniqure from a “sell” rating to a “hold” rating in a research note on Tuesday, December 26th. Finally, BidaskClub upgraded Uniqure from a “hold” rating to a “buy” rating in a research note on Wednesday, December 27th. One analyst has rated the stock with a sell rating, four have issued a hold rating and six have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $20.00.
Uniqure (QURE) traded down $0.02 on Wednesday, hitting $18.48. The stock had a trading volume of 392,159 shares, compared to its average volume of 416,521. The stock has a market cap of $569.19, a PE ratio of -7.08 and a beta of 0.72. The company has a current ratio of 3.64, a quick ratio of 3.64 and a debt-to-equity ratio of 0.73. Uniqure has a 52 week low of $4.72 and a 52 week high of $21.35.
Uniqure (NASDAQ:QURE) last released its earnings results on Wednesday, November 1st. The biotechnology company reported ($0.40) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.65) by $0.25. Uniqure had a negative return on equity of 170.28% and a negative net margin of 338.39%. sell-side analysts predict that Uniqure will post -2.97 EPS for the current fiscal year.
In other news, Director David Schaffer sold 2,878 shares of the business’s stock in a transaction on Monday, January 29th. The stock was sold at an average price of $18.53, for a total value of $53,329.34. Following the completion of the transaction, the director now owns 15,314 shares in the company, valued at $283,768.42. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Christian Klemt sold 5,093 shares of the business’s stock in a transaction on Wednesday, January 3rd. The stock was sold at an average price of $20.13, for a total value of $102,522.09. The disclosure for this sale can be found here. Insiders sold 41,510 shares of company stock valued at $815,776 in the last 90 days. Company insiders own 0.73% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of QURE. First Manhattan Co. bought a new stake in shares of Uniqure in the fourth quarter worth $1,371,000. Mangrove Partners grew its holdings in shares of Uniqure by 167.4% in the third quarter. Mangrove Partners now owns 106,634 shares of the biotechnology company’s stock worth $1,024,000 after acquiring an additional 66,763 shares during the period. Victory Capital Management Inc. bought a new stake in shares of Uniqure in the fourth quarter worth $1,298,000. FMR LLC grew its holdings in shares of Uniqure by 4.1% in the second quarter. FMR LLC now owns 1,560,113 shares of the biotechnology company’s stock worth $9,656,000 after acquiring an additional 61,650 shares during the period. Finally, OxFORD Asset Management LLP bought a new stake in shares of Uniqure in the third quarter worth $399,000. 24.95% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: “Uniqure (QURE) Downgraded by Zacks Investment Research” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/02/01/uniqure-qure-downgraded-to-sell-at-zacks-investment-research.html.
Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships.
Get a free copy of the Zacks research report on Uniqure (QURE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.